In This Article:
In the current global market landscape, investors are navigating a complex environment marked by tariff uncertainties and mixed economic signals, with major indices experiencing slight declines amid these challenges. Despite this volatility, some stocks may present opportunities for value-oriented investors who are seeking assets potentially priced below their estimated worth. Identifying such undervalued stocks requires careful analysis of financial fundamentals and market conditions to uncover potential discrepancies between a company's intrinsic value and its current market price.
Top 10 Undervalued Stocks Based On Cash Flows
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Provident Financial Services (NYSE:PFS) | US$18.71 | US$37.36 | 49.9% |
| KG Mobilians (KOSDAQ:A046440) | ₩4445.00 | ₩8850.75 | 49.8% |
| Alarum Technologies (TASE:ALAR) | ₪3.356 | ₪6.68 | 49.7% |
| Celsius Holdings (NasdaqCM:CELH) | US$21.28 | US$42.43 | 49.8% |
| Aoshikang Technology (SZSE:002913) | CN¥29.12 | CN¥57.92 | 49.7% |
| S&U (LSE:SUS) | £16.25 | £32.33 | 49.7% |
| Similarweb (NYSE:SMWB) | US$11.87 | US$23.62 | 49.7% |
| Neosperience (BIT:NSP) | €0.53 | €1.06 | 49.9% |
| Medy-Tox (KOSDAQ:A086900) | ₩119200.00 | ₩235487.26 | 49.4% |
| Kyndryl Holdings (NYSE:KD) | US$41.15 | US$81.37 | 49.4% |
Underneath we present a selection of stocks filtered out by our screen.
Türk Telekomünikasyon Anonim Sirketi
Overview: Türk Telekomünikasyon Anonim Sirketi, along with its subsidiaries, functions as an integrated telecommunication company in Turkey with a market cap of TRY174.79 billion.
Operations: The company's revenue is primarily derived from its Fixed-Line segment at TRY67.30 billion and Mobile segment at TRY45.38 billion.
Estimated Discount To Fair Value: 14.5%
Türk Telekomünikasyon Anonim Sirketi is trading at TRY49.94, below its estimated fair value of TRY58.38, representing a 14.5% discount. Despite being only moderately undervalued based on discounted cash flow analysis, the company shows robust growth potential with earnings expected to grow significantly at 32% annually over the next three years and revenue projected to rise by 27.3% per year, outpacing market growth rates in Turkey.
GemPharmatech
Overview: GemPharmatech Co., Ltd. is a contract research organization offering genetically engineered mouse models and preclinical research services globally, with a market cap of CN¥6.42 billion.